To evaluate the efficacy safety and tolerability of 6-week extended interval dosing of Natalizumab (BG00002) switching from treatment with 4-Week Natalizumab standard interval dosing (SID) in relation to continued SID treatment

Brief description of study

The main purpose of this study is to evaluate the efficacy, safety, and tolerability of 6-week extended interval dosing of Natalizumab (BG00002) switching from treatment with 4-Week Natalizumab standard interval dosing (SID) in relation to continued standard interval dosing (SID) treatment.


Clinical Study Identifier: s18-01090
ClinicalTrials.gov Identifier: NCT03689972
Principal Investigator: Lana Zhovtis Ryerson.
Other Investigator: Erica Parrotta.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.